Andrew Hau

Andrew Hau has over fourteen years of work experience in the field of biology and pharmacology. Andrew began their career in 2006 as a Research Assistant at the University of Arizona, Department of Pharmacology and Toxicology, where they studied oncogenic signaling pathways involved in arsenic-induced carcinogenesis of urothelial cells. In 2007, they joined Oregon State University as a Graduate Research Assistant in the Department of Pharmaceutical Sciences, where they investigated the MOA of the anti-tumor natural product coibamide A in human glioblastoma cells. During their time there, they contributed to three co-author publications, trained and supervised graduate and undergraduate research assistants, and managed and instructed undergraduate courses. In 2013, they became a Postdoctoral Scholar at the University of California San Diego, Department of Pathology, where they identified high-yield, targetable biomarkers and pathways in invasive bladder cancer, with a specific emphasis on mTOR signaling. Andrew also introduced bioinformatics approaches to the lab. In 2019, they joined Sorrento Therapeutics, Inc. as a Senior Scientist in ADC (in vitro Biology), and later as a Scientist II in the same role. Most recently, in 2021, they joined Adcentrx Therapeutics as a Principal Investigator in Discovery Biology and a Principal Scientist in Research.

Andrew Hau attended Oregon State University from 2007 to 2012, where they earned a Doctor of Philosophy (PhD) in Pharmaceutical Sciences. Prior to that, they attended the University of Arizona from 2002 to 2006, where they earned a BS in Biochemistry, Biophysics and Molecular Biology.